Clinical development teams face constant pressure to accelerate timelines, improve enrollment performance, and reduce operational risk. Yet despite advances in trial technology, one challenge continues to impact study success: clinical trial site selection. Selecting the right sites can determine whether a study meets enrollment goals on time or struggles with costly delays, protocol deviations, and underperforming investigators.

Today, sponsors are increasingly turning to artificial intelligence (AI) to modernize the site selection process. Rather than relying solely on historical relationships, feasibility questionnaires, and manual analysis, organizations are leveraging AI-driven insights to identify the best sites, recruit patients faster, and optimize protocols before the first patient is enrolled.

Why Clinical Trial Site Selection Matters More Than Ever

Clinical trials have become increasingly complex. Protocols require larger datasets, more endpoints, broader geographic reach, and greater patient diversity than ever before. At the same time, sponsors continue to face enrollment challenges that threaten study timelines and budgets.

A poor site selection strategy can lead to:

Slow enrollment rates
High screen failure rates
Increased protocol deviations
Underperforming sites
Delayed study milestones
Higher operational costs

Sponsors often face challenges related to study startup, site feasibility, activation support, enrollment performance, and clinical trial oversight. These operational hurdles often originate long before a study begins, making site selection one of the most critical decisions in the clinical development lifecycle.

Moving Beyond Traditional Site Selection Models

Historically, site selection has relied heavily on investigator relationships, prior experience, feasibility surveys, and self-reported site capabilities. While these inputs remain valuable, they often provide an incomplete picture of future site performance.

AI is enabling a more data-driven approach.

Modern AI platforms can analyze vast amounts of historical and real-world data simultaneously, including:

Previous site performance metrics
Enrollment rates
Screen failure trends
Investigator experience
Patient population demographics
Electronic health record (EHR) data
Geographic disease prevalence
Site startup timelines
Data quality indicators

By evaluating these variables together, AI can identify patterns that are difficult or impossible for human teams to detect through manual review alone. External industry research demonstrates that AI-powered site selection helps sponsors predict which locations are most likely to recruit eligible patients efficiently while maintaining quality performance standards.

AI-Powered Patient Recruitment Starts with Site Selection

One of the most significant advantages of AI-driven clinical trial site selection is its direct connection to patient recruitment.

For years, sponsors have struggled with the mismatch between projected patient availability and actual enrollment outcomes. AI helps close that gap by providing a more accurate view of where eligible patient populations exist.

Using machine learning models, sponsors can analyze structured and unstructured healthcare data to better understand:

Disease prevalence by geography
Demographic characteristics
Treatment patterns
Referral networks
Physician relationships
Patient eligibility criteria

This allows organizations to prioritize sites that have demonstrable access to the right patient populations rather than relying solely on site projections.

AI can also support pre-screening efforts by matching protocol criteria against real-world patient datasets. As a result, sites can identify potential candidates faster, reduce manual screening activities, and accelerate enrollment timelines. Industry experts increasingly view AI-enabled patient matching as one of the highest-value applications of AI within clinical operations.

Protocol Optimization Enhances Site Feasibility

Another emerging use of AI is protocol optimization.

Sponsors often discover too late that protocol requirements create unexpected barriers to enrollment or execution. Excessively restrictive inclusion criteria, burdensome visit schedules, or complex procedures can limit patient eligibility and reduce site participation.

AI allows sponsors to evaluate protocols before activation by simulating potential enrollment outcomes and identifying operational risks.

These insights help study teams:

Refine inclusion and exclusion criteria
Simplify patient participation requirements
Improve protocol feasibility
Reduce site burden
Increase enrollment potential
Enhance patient retention

Eliassen Group's clinical research insights have highlighted growing industry interest in using AI to identify more effective inclusion and exclusion criteria while improving patient identification, engagement, and retention strategies. As protocols become increasingly patient-centric, AI provides an additional layer of evidence that can improve study design decisions before costly execution challenges emerge.

Predicting Site Performance Before Problems Occur

Perhaps the most transformative capability of AI in clinical trial site selection is predictive analytics.

Rather than evaluating sites based only on historical performance, AI can forecast future outcomes by analyzing multiple risk factors simultaneously.

Sponsors can gain visibility into potential challenges such as:

Enrollment shortfalls
Activation delays
Resource constraints
Staffing limitations
Compliance risks
Data quality concerns

This proactive approach enables clinical operations teams to mitigate risks earlier and allocate resources more effectively.

Additionally, AI-powered monitoring tools can continue evaluating site performance after activation, providing near real-time insights into recruitment trends, patient retention, and operational metrics. This continuous visibility supports faster decision-making and helps sponsors keep studies on track.

The Future of Clinical Trial Site Selection

AI will not replace the expertise of clinical operations leaders, trial managers, or investigators. Instead, it will augment their decision-making capabilities by providing deeper insights and stronger predictive intelligence.

As clinical trials become more complex, sponsors need smarter ways to identify high-performing sites, reach eligible patients, and optimize protocols. Organizations that successfully integrate AI into their clinical trial site selection strategy will be better positioned to reduce delays, improve enrollment performance, and accelerate development timelines.

Eliassen Resources:

White paper: Promise and Peril: Navigating What’s Next in Clinical Research

Webinar: Bridging Innovation & Patient Care

Sources:

Optimizing clinical trial site performance: A focus on three AI capabilities | IBM

Agentic AI for Clinical Trial Site Selection

How AI Is Transforming Clinical Trials | AHA